Recent Non-Hodgkin's Lymphoma News

Xalkori® Receives FDA Breakthrough Therapy Designation for Anaplastic Large Cell Lymphoma

(July 3, 2018)

The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for Xalkori® (crizotinib) for the treatment of patients with relapsed or refractory systemic anaplastic large cell... Continue Reading


FDA Grants Approval of Calquence for the Treatment of Mantle Cell Lymphoma

(May 31, 2018)

The US Food and Drug Administration (FDA) has granted approval to Calquence (acalabrutinib) for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Calquence... Continue Reading


FDA Approves Aliqopa for Relapsed Follicular Lymphoma

(May 23, 2018)

The U.S. Food and Drug Administration (FDA) granted accelerated approval to Aliqopa® (copanlisib), a novel precision cancer medicine that inhibits phosphatidylinositol 3-kinase (PI3K), for the treatment... Continue Reading


FDA Approves Kymriah for Treatment of Relapsed or Refractory Large B-Cell Lymphoma

(May 21, 2018)

On May 1, 2018, the United States Food and Drug Administration (FDA) approved Kymriah (tisagenlecleucel), a CD19-directed genetically modified autologous T-cell immunotherapy, for treatment of adult patients... Continue Reading


Keytruda Effective in Patients with Relapsed or Refractory Lymphoma

(January 23, 2018)

CancerConnect News: Findings from the KEYNOTE-170 clinical trial Presented at the 59th American Society of Hematology (ASH) Annual Meeting suggest that the novel immunotherapy medication keytruda® (pembrolizumab)... Continue Reading


FDA approves Gazyva for previously untreated follicular lymphoma

(January 11, 2018)

CancerConnect News: The United States Food and Drug Administration granted regular approval to Gazyva (obinutuzumab) in combination with chemotherapy, followed by Gazyva monotherapy in patients achieving... Continue Reading


Mogamulizumab Superior to Vorinostat in Cutaneous T Cell Lymphoma

(December 13, 2017)

Results were recently presented at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta from a international comparative clinical trail evaluating mogamulizumab in patients... Continue Reading


Seattle Genetics Announces FDA Approval of ADCETRIS® (Brentuximab Vedotin) for Primary Cutaneous Anaplastic Large Cell Lymphoma (pcALCL) and CD30-Expressing Mycosis Fungoides (MF)

(November 15, 2017)

-MF and pcALCL Represent the Most Common Subtypes of Cutaneous T-Cell Lymphoma (CTCL)- -FDA Approval Based on Clinical Trial Results from the Phase 3 ALCANZA and Phase 2 Investigator-Sponsored Studies... Continue Reading


FDA approves Calquence Treatment for Treatment of Mantle Cell Lymphoma

(November 6, 2017)

The U.S. Food and Drug Administration has granted accelerated approval to Calquence (acalabrutinib) for the treatment of adults with mantle cell lymphoma who have received at least one prior therapy. ... Continue Reading


Keytruda® Significantly Prolongs Survival Compared to Chemotherapy First-Line Treatment for Advanced Non-Small Cell Lung Cancer

(October 23, 2017)

Updated study results presented at the World Congress on Lung Cancer this week continue to demonstrate that treatment of advanced non small cell lung cancer (NSCLC) whose tumors expressed high levels of... Continue Reading


Next Page »